- By ICR Secretariat
- Posted Thursday, April 28, 2022
How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials
https://www.biopharmadive.com/news/alnylam-ttr-cardiomyopathy-apollo-bridge-bio-trial/622480/
The outcome, no longer seen as a sure bet, could influence how future drugs for a deadly heart disease are developed.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- FDA rejects two China-developed cancer drugs 19/05/2022 03:45 PM
- University launches hub for pregnant women with pre-existing medical conditions 19/05/2022 03:44 PM
- Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class 19/05/2022 03:42 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org